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Pre-term birth (PTB) associated with intrauterine infection and inflammation (IUI) is the
major cause of early PTB less than 32 weeks of gestation. Ureaplasma spp. are common
commensals of the urogenital tract in pregnancy and are the most commonly identified
microorganisms in amniotic fluid of pre-term pregnancies. While we have an understand-
ing of the causal relationship between intra-amniotic infection, inflammation and PTB, we
are still unable to explain why vaginal Ureaplasma sp. colonization is tolerated in some
women but causes PTB in others. It is now known that placental tissues are frequently
colonized by bacteria even in apparently healthy pregnancies delivered at term; usually this
occurs in the absence of a significant local inflammatory response. It appears, therefore,
that the site, nature, and magnitude of the immune response to infiltrating microorganisms
are key in determining pregnancy outcome. Some evidence exists that the maternal sero-
logical response to Ureaplasma sp. colonization may be predictive of adverse pregnancy
outcome, although issues such as the importance of virulence factors (serovars) and the
timing, magnitude, and functional consequences of the immune response await clarifica-
tion. This mini-review discusses the evidence linking the maternal immune response to
risk of PTB and the potential applications of maternal serological analysis for predicting
obstetric outcome.
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INTRODUCTION
It is estimated globally that approximately 12 million babies are
born pre-term each year, making the prevention of pre-term
birth (PTB) one of the highest priorities for international obstet-
ric research (1). Intrauterine infection (IUI) and subsequent
inflammation of the extra-placental membranes (chorioamnioni-
tis) accounts for approximately 40% of all spontaneous PTBs and
is the major cause of early PTB (<32 weeks of gestation). IUI is
typically“silent”(undiagnosed) until the onset of pre-term labor at
which point it is often too late for treatment as chorioamnionitis is
well established, the risk of fetal inflammatory response syndrome
(FIRS) is high (2), and tocolysis is ineffective. Identifying women
at risk of infection-associated PTB sufficiently early in pregnancy
to allow therapeutic intervention would be a significant advance
in the prevention of PTB.
Traditional thinking associates IUI with the ascension of bacte-
ria from cervicovaginal fluid, resulting in intra-amniotic infection
and immune stimulation within the otherwise sterile intrauterine
environment (3). It is now clear, however, that the placenta and
extra-placental membranes can no longer be considered strictly
sterile (4, 5). Instead, they are home to a unique microbiome of
non-pathogenic commensals; the presence of which is normal and
not associated with early delivery or adverse pregnancy outcomes
(4, 6). Histological and immunological analysis of intrauterine
tissues and fluids suggests that the nature and magnitude of
inflammatory response associated with bacterial colonization may
be key in determining obstetric outcome (6–8).
Recent placental microbiological studies have reignited debate
regarding the role of differential virulence (9), poly-microbial
interactions (10), host genetics (11), and immune factors (12)
in determining obstetric outcome. While attention has primarily
been placed on defining the local immune response to bacteria
within placental tissues, the role and significance of the mater-
nal systemic immune response to the infection has been largely
neglected. Yet, studies conducted at the end of the last century
strongly suggested that the maternal immune response to com-
mensal microorganisms found in the urogenital tract in preg-
nancy – in particular the Ureaplasma species – may provide us
with important clues as to why some women are at risk of adverse
pregnancy outcomes while the majority are not.
In this mini-review, we discuss in detail the somewhat contra-
dictory evidence relating to the presence and nature of maternal
antibodies to Ureaplasma sp. and their significance in determining
and predicting obstetric outcome. A specific focus is placed on the
potential clinical utility of serological analysis in the identification
of women at elevated risk of PTB.
UREAPLASMA AND PTB
Ureaplasma spp. are generally considered commensal microor-
ganisms (13–16) and are classified into two species and 14
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distinct serovars (SV). SV1, SV3, SV6, and SV14 belong to
U. parvum species and the remaining ten SV to U. urealyticum
(17). Ureaplasma sp. commonly colonize the urogenital tract of
both males and females (18, 19). Vaginal colonization rates can
vary greatly in non-pregnant women (up to 70%) (20, 21) and
women with uncomplicated pregnancies [2.7–70%; reviewed in
Ref. (22)]. Ureaplasma spp. are some of the most frequently identi-
fied microorganisms in placental tissues and amniotic fluids (AF)
from pre-term deliveries (23–25). Colonization of the placenta
with Ureaplasma sp. has been demonstrated to be an independent
risk factor for chorioamnionitis [odds ratio (OR), 11.27; 95% CI,
5.09–24.98] (7). Detection rates in AF vary from 0% to 19% in
early mid-trimester (26–28), to 2–80% at pre-term labor (26, 29)
and 18–100% with pre-labor premature rupture of membranes
(PPROM) (26, 30). A meta-analysis of 22 studies found a signif-
icant association between the presence of Ureaplasma sp. in the
vagina and AF with PTB (22). However, Ureaplasma sp. coloniza-
tion in the urogenital tract and AF is a relatively common finding
in pregnant women and alone it is not sufficiently predictive of
PTB to be clinically useful (8).
The reasons why commensal Ureaplasma sp. cause ascending
IUI leading to PTB in only a subset of women are still unknown but
are likely to be complex and multifactorial (Figure 1). SV-specific
virulence has been proposed as an important determinant of risk
of adverse outcome. Of the two Ureaplasma species, U. parvum
is the most commonly isolated species from clinical samples (31),
with two of its SV – SV3 and SV6 – associated with worse preg-
nancy outcomes (32–34). Unfortunately, most studies of IUI do
not differentiate between Ureaplasma SV so data on the relation-
ship between SV prevalence and risk are lacking. Poly-microbial
interactions may also be significant as diagnosis of abnormal bac-
terial flora or bacterial vaginosis (BV) (i.e., a high Nugent score) is
also a risk factor for PTB (35), independent of Ureaplasma sp. colo-
nization status. It is worth noting that poly-microbial colonization
of the amniotic cavity is common in pre-term deliveries, with
around half of all infected AF containing two or more microor-
ganisms (23). Co-colonization of the vagina with a Ureaplasma sp.
and another genital Mycoplasma sp. has been reported to be asso-
ciated with more severe adverse pregnancy outcomes compared
to colonization with a single organism (36). Competence of the
cervical barrier to microbial ascension is also likely to play a role
in determining risk of PTB. A short cervix in pregnancy has been
associated with increased risks of microbial colonization (37) and
spontaneous PTB (38, 39).
Finally, maternal/fetal immunological tolerance or compe-
tence is a likely determinant of obstetric outcome associated
FIGURE 1 | Factors affecting ascension of vaginal Ureaplasma sp. and risk of adverse pregnancy outcomes.
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with colonization by Ureaplasma sp. and other microorgan-
isms. Surface-exposed lipoproteins of Ureaplasma sp. activate
the pro-inflammatory transcription factor NF-κB through TLR
ligation (40, 41), although exposure of intrauterine tissues to
Ureaplasma sp. does not generally trigger a robust inflamma-
tory response. Nevertheless, intra-amniotic infection with U.
parvum has been causally linked to chorioamnionitis, FIRS
and PTB in animal models (42–44). This is consistent with
observations from clinical studies showing that chorioamnioni-
tis/funisitis is more likely in pregnancies infected with Ureaplasma
sp. as opposed to other bacteria (7). On the other hand, most
women with vaginal colonization and local inflammatory response
will not deliver preterm (24, 45). Combs, Gravett (8), pro-
posed a model of IUI comprising of five subgroups: (1) micro-
bial colonization plus inflammation (AF IL-6 >11.3 ng/ml); (2)
severe inflammation with no detectable microorganisms (AF
IL-6 >11.3 ng/ml); (3) mild inflammation with no detectable
microorganisms (AF IL-6 of 2.6–11.2 ng/ml); (4) microbial col-
onization with no inflammation; and (5) absence of infection
or inflammation. This more complicated scenario highlights the
need to accurately stratify women at risk of PTB associated
with IUI.
MATERNAL ANTIBODIES AGAINST UREAPLASMA FOR THE
PREDICTION OF PTB
ANTI-UREAPLASMA SERUM ANTIBODIES IN PATHOGENESIS OR
PROTECTION FROM DISEASE
Specific antibodies may be produced in response to a bacterial
infection and detected in the serum (seropositivity). Antibod-
ies act to neutralize bacterial toxins, facilitate opsonization, and
together with the complement system work toward clearance
of the infection. Antibodies generated against surface-exposed
Ureaplasma sp. epitopes have been identified and shown to inhibit
Ureaplasma sp. metabolism (46) and support complement medi-
ated Ureaplasma sp. clearance (47) suggestive of a protective
effect. Interestingly, individuals with the greatest number/intensity
of anti-Ureaplasma antibody bands by immunoblot appeared
to have higher Ureaplasma sp. killing ability (47). These data
are in contrast with other studies which report that the pres-
ence of anti-Ureaplasma antibodies in colonized pregnant women
are associated with worse pregnancy outcome [reviewed in Ref.
(26); see Anti-Ureaplasma Antibodies as Biomarkers for IUI and
PTB below]. In these circumstances, it is likely that seropos-
itivity is pathologic rather than protective, possibly acting via
an exacerbation of inflammatory processes triggering PTB (48).
This concept is supported by data from a pregnant sheep model
of intra-amniotic Ureaplasma sp. infection, in which increased
intrauterine inflammation was detected in sheep in which mater-
nal anti-Ureaplasma IgG was also detected (9). Alternatively, it
may be the absence of a specific antibody that confers protection
from PTB. The key to unraveling this confusion is the iden-
tification of antigen–antibody characteristics associated with a
given pregnancy outcome to determine whether it is antibody
abundance (i.e., titer), nature of the target (i.e., virulence fac-
tor), onset of response (time of exposure), or capacity to induce
microbial lysis and destruction that is associated with risk of
PTB.
ANTI-UREAPLASMA ANTIBODIES AS BIOMARKERS FOR IUI AND PTB
In the 1980–1990s, several research groups investigated the anti-
body response to Ureaplasma sp. as a biomarker for intra-amniotic
or urogenital infections (49–51). A review on the topic of assess-
ment of antibodies for identification of intra-amniotic infec-
tion with Ureaplasma sp. during pregnancy was published in
1994 by Shulamith Horowitz (26). He reviewed the literature
and correlated cervical and intra-amniotic Ureaplasma sp. col-
onization rates with the presence of antibody and pregnancy
outcome. Specifically, he found that a greater percentage of
women had adverse pregnancy outcomes if they had positive
Ureaplasma sp. AF cultures and elevated serum anti-Ureaplasma
antibody titers at either genetic amniocentesis, or pre-term labor
with/without PPROM (defined as fetal loss, stillbirth, pre-term
delivery, or low birth weight) (Figure 2A) (26). Odds ratios and
relative risks for adverse pregnancy outcome in culture-positive
(C+) /antibody-positive (Ab+) women vs. C+/antibody-negative
(Ab−) women were calculated based on these data and are pre-
sented in Figure 2B. Despite some discrepancy between studies,
the detection of anti-Ureaplasma IgG in maternal sera together
with AF colonization was predictive of an increased risk of devel-
oping pregnancy complications [OR: 81.00 at genetic amniocen-
tesis (p= 0.04); OR: 24.56 (p= 0.04); and RR: 2.31 (p= 0.02) at
PPROM]. Despite these encouraging findings, this line of research
has not matured over the proceeding decades for the reasons
outline below.
FACTORS THAT HAVE LIMITED THE CLINICAL TRANSLATION OF
MATERNAL ANTIBODY DETECTION FOR PREDICTION OF PTB
Unfortunately, routine amniocentesis for the purpose of diagnos-
ing intra-amniotic colonization with Ureaplasma sp. is not clini-
cally feasible due to the procedure-associated risk of spontaneous
miscarriage (RR 1.60; 95% CI 1.02–2.52) (52). Furthermore, the
rates of Ureaplasma sp. colonization of AF in mid pregnancy are
actually very low (22, 26, 27). As such, consideration has been given
to the ability of maternal antibodies alone to stratify pregnant
women for risk of PTB.
SEROCONVERSION IN RESPONSE TO UREAPLASMA IS COMMON
Early studies varied in their reported rates of seroconversion.
ELISA based studies reported anti-Ureaplasma IgG seropositiv-
ity rates of 50–85% in culture-positive individuals and 6–15%
in culture-negative individuals (46, 53, 54). However, these stud-
ies reported positive cutoffs based on maximum detection in
culture-negative cohorts, assuming culture-negative individuals to
be seronegative (53, 54). Others have since shown by immunoblot
that seroconversion is more common, with greater than 80% of
sera from healthy non-pregnant individuals (47) recognizing at
least one Ureaplasma sp. antigen (IgG response). As the serocon-
version rate is high in both colonized and non-colonized individ-
uals, several studies used a method of serum dilution for assigning
positivity to sera with elevated titers (46, 55). It is still unclear
whether differences between patients with slightly elevated vs. very
high levels of antibodies are clinically significant. As colonization
is so common, it is most likely that seropositivity in non-colonized
individuals represents a persistent antibody to a cleared infection.
Nevertheless, high seroconversion rates mean that detection of
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FIGURE 2 | Pregnancy outcome in relation to culture-positive (C+) AF
and anti-Ureaplasma antibodies (Ab+) in maternal serum.
(A) Ureaplasma sp. detected by culture technique. Antibodies determined
by ELISA and semi-quantitation of antibody titer; adverse pregnancy
outcome defined as fetal loss, stillbirth, pre-term delivery, and low birth
weight. Genetic amniocentesis was performed at 16–20 weeks of
gestation; no gestational age provided for the PTL and PPROM groups.
(B) Odds ratios (OR) and relative risks (RR) for adverse pregnancy outcome
in culture-positive/antibody-positive (C+Ab+) vs. C+Ab− were calculated for
each group. Data extracted and adapted from Horowitz et al. (26).
IgG antibody responses to whole cell lysates or isolated membrane
antigens is unlikely to be clinically useful.
SEROVAR-SPECIFIC UREAPLASMA ANTIGENS AND CROSS-REACTIVITY
U. parvum SV3 and SV6 are most commonly associated with
worse pregnancy outcome (32–34). The possibility of a SV-specific
antibody response to Ureaplasma sp. was proposed following the
identification of apparent SV-specific antigens. For example, an
85 kDa protein in SV1, a 71 kDa protein from SV3, 61 kDa and
55 kDa proteins from SV6, and an 88 kDa protein from SV14
have all been identified (56). However, there is extensive antigen
cross-reactivity among all SV with the evidence for SV specificity
strongest in individual cases. It is likely that the multiple-banded
antigen (MBA) is a key virulence factor for Ureaplasma sp. (57),
containing both SV-specific and conserved/cross-reactive epitopes
(58). The MBA, a surface-expressed diacylated lipoprotein, is rec-
ognized by TLRs 1, 2, 6 (40), and 9 (41) and has a molecular weight
of approximately 70–90 kDa (59), but migrates as a symmetrical
ladder pattern between 55 and 75 kDa on immunoblot due to
conformational folding (58). The mba gene exists as a single copy
within the Ureaplasma sp. genome (60). The precise immuno-
genic MBA epitopes are still unknown but are considered to be
within the size-variable and surface-exposed C-terminal region
(58). Mutations in the mba gene have been proposed to play an
important role in helping the organism evade the host immune
system (60) with multiple mechanisms proposed (58–61).
Serum from Ureaplasma sp. colonized individuals detect mul-
tiple and likely closely related antigens forming the ladder seen
on immunoblots. The identity of specific immunodominant epi-
topes and their role in differential pathogenesis in pregnancy
remains unclear and is further complicated by the variability of
the MBA. A number of cases where mother-fetus dyads appeared
to be colonized with different SV and generated different anti-
body responses (as determined by ELISA) have been observed
(62). It needs to be remembered that Ureaplasma spp. are fastid-
ious organisms, and without careful collection and appropriate
culture protocols their presence may have been missed (63). Mol-
ecular methods, in combination with routine culture, are now
preferred for the detection and speciation of Ureaplasma sp. in
clinical samples (64).
The lack of robust and reliable techniques to differentiate
between SV, the diversity of responses among individuals and the
cross-reactivity between SV have significantly compromised the
ability to use antibody responses beyond the simple determina-
tion of seroconversion. Clarification of the relationship between
SV-related antigens, microbial virulence, and differential systemic
immune responses will be required to resolve the present impasse.
FETAL ANTIBODY RESPONSES TO UREAPLASMA AND OBSTETRIC
OUTCOME
While our emphasis has been on the maternal immune response as
a determinant of obstetric outcome, fetal systemic responses can
undoubtedly contribute to progression to PTB (65). In utero expo-
sure to Ureaplasma sp. is commonly associated with increased inci-
dence of neonatal complications including bronchopulmonary
dysplasia, intraventricular hemorrhage, necrotizing enterocolitis,
and pneumonia (66–69). Fetal production of antibody against
Ureaplasma sp. has been reported (70–72), with antibody detected
at birth in neonates as young as 22–27 weeks of gestation. More-
over, antibody titer appears to correlate negatively with neonatal
outcome. IgM has been detected in the fetus/neonate consistent
with an initial stage of immune recognition (62). In the sheep
model, anti-Ureaplasma IgG has also been detected in fetal serum,
with one case reported where the antibodies in maternal and
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fetal sera recognized different antigens (9). Furthermore, fetuses
which developed systemic Ureaplasma sp. infection [culture-
positive cerebrospinal fluid (CSF)] were found in ewes with the
lowest numbers of MBA variants in AF and the highest mono-
cyte count in the chorioamnion (61). Thus, monitoring maternal
responses alone may fail to identify the fetuses at most risk in utero.
Unfortunately, acquiring blood antenatally for determination of
fetal seroconversion is not a practical approach for assessing risk
of PTB.
CELLULAR RESPONSES TO UREAPLASMA
Ureaplasma sp. have been shown to stimulate pro-inflammatory
responses in fetal membranes (73), choriodecidual explants (74),
and preterm and term cord blood (75). However, studies of white
blood cell responses to Ureaplasma sp. in pregnancy have not
proven to be useful to date, with no differences in responsiveness
observed in leukocytes from women at risk of PTB compared to
those with normal pregnancies (12). Reyes et al. explained differ-
ential pathogenesis of Ureaplasma sp. in urinary tract infections
(UTIs) by demonstrating the presence of two distinct immune
cell profiles (76). Asymptomatic UTIs were characterized by min-
imal monocytic and lymphocytic infiltration, less tissue damage
and increased IFN-γ, while complicated UTIs were associated with
greater concentrations of pro-inflammatory cytokines, extensive
inflammation and predominantly a neutrophilic response. No
comparable data from pregnant women have been published to
date. Recently, unconventional lipid antigens such as those present
in Ureaplasma sp. (9, 57), and microbe-derived vitamin B metabo-
lites (77), have also been shown to stimulate T cell responses vital
for microbial clearance (78, 79). However, the role of these uncon-
ventional T cells in the response to Ureaplasma sp. in the context of
pregnancy immunity and PTB risk remains unknown and the role
of the systemic immune cell responses to Ureaplasma sp. exposure
in pregnancy remains relatively unexplored.
CONCLUDING REMARKS
Despite advances in our understanding of the causal relationships
between intrauterine infection and PTB, major research ques-
tions remain unanswered: is there a subpopulation of patients
in which Ureaplasma sp. colonization correlates with worse dis-
ease outcome? Does the site of colonization determine disease
outcome? Are there pathogenic and non-pathogenic SV deter-
mining disease outcome? Is there a specific aspect of the maternal
immune response to Ureaplasma sp. infection that influences risk
of PTB?
Research on specific Ureaplasma sp. SV and virulence factors
have failed to yield conclusive results. Despite the earlier clini-
cal promise of antibody-based predictive approaches (26, 62), the
assessment of maternal or fetal seropositivity to identify women
for prophylactic treatment has not made it into clinical practice.
It is unclear when and where exposure to Ureaplasma sp. antigens
takes place in pregnancy and when/how commensal colonization
becomes an infection. As such, it is difficult to define the role of
antibodies in pathogenesis. Antibody cross-reactivity among the
Ureaplasma SV and lack of stringent proof of epitope specificity
have also limited attempts to use an individual’s antibody response
to make a SV-specific diagnosis of infection or predict an outcome.
Before an antibody-based immunological test can be consid-
ered as part of a routine antenatal screen, future studies must
address technical and scientific issues surrounding the detec-
tion and antigen characterization of antibodies to Ureaplasma
sp. (41, 46, 47, 54, 58). Key issues to be addressed include: (i)
need for the identification of the colonizing SV; (ii) requirement
for the detection of a SV-specific or global antibody response;
(iii) characterization of immunodominant epitopes; (iv) defining
the difference between commensal colonization and infection; (v)
determining when and where Ureaplasma sp. are first immunolog-
ically detected; and (vi) characterizing the kinetics and magnitude
of the antibody response in relation to pregnancy outcome. Based
on current knowledge, it seems that the detection and measure-
ment of uncharacterized maternal antibodies against Ureaplasma
sp. has limited predictive value for identifying women at elevated
risk of infection-driven PTB.
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